Specialist-grade lung measurements to home use for chronic lung conditions: design for manufacture and clinical feasibility

这是一个由AMT领导的项目，与CLCH NHS信托的共同申请伙伴，以及制造中小企业分包商。该解决方案解决了与慢性呼吸道疾病（CRD）相关的主要挑战。该项目大量涉及NHS内部的利益相关者和用户输入，旨在通过以用户为中心的设计和临床医生和患者的共同开发，将Respicorder从临床原型开发为家庭远程监测和自我管理解决方案。为了充分了解肺功能，需要进行多次测量。目前还没有设备能结合这些测量，而且目前的解决方案要么价格昂贵，要么不适合家庭使用、自我管理或远程监控。CRD目前很少或根本没有针对这些途径的有效解决方案，导致管理不善和高水平的恶化（发作），这反过来又导致昂贵的治疗费用和住院和急诊次数增加。三个主要挑战是：(i)没有黄金标准测量，（ii）病情每天都在变化（可与糖尿病相比），以及（iii）有数十种需要个性化治疗的病情亚型。以前，不可能从经济上克服这些挑战，但它们是可以克服的。Respicorder已经证明了其核心技术，下一阶段的进展是向可行的家用产品扩展（制造工艺/成本和可用性）。该设备是手持、便携的，日常家庭使用，可以识别呼吸道疾病亚型，并通过随附的呼吸数字中心（RDH）预测风险水平。通过这种方式支持患者，我们可以让人们远离医院，更好地控制他们的病情，提供更有效的治疗。

This is a project led by AMT, with co-applicant partner of CLCH NHS Trust, and with manufacturing SME sub-contractors. The solution tackles the major challenges associated with Chronic Respiratory Diseases (CRD's).The project heavily involves stakeholders within the NHS and user inputs and aims to develop the Respicorder from an in-clinic prototype towards an at-home remote monitoring and self-management solution, through user-centric design and co-development with clinicians and patients.To generate a full understanding of lung performance, multiple measurements are required. No device currently combines these measurements, and current solutions are expensive or not appropriate for at-home use, for self-management or remote monitoring. CRD's currently have little or no effective solution for such pathways, leading to poor management and high levels of exacerbations (attacks), which in turn lead to expensive treatment costs and increased hospital admissions and emergency visits.The three main challenges are: (i) there is no gold standard measurement, (ii) there are daily changes in condition (comparable to diabetes), and (iii) there are dozens of condition subtypes requiring personalised treatment. Previously, it has not been possible to economically overcome these challenges, but they are surmountable.The Respicorder has proven its core technology and the next stages of progress are for extension towards a viable at-home-use product (manufacturing processes / costs and usability). The device is handheld, portable, and with daily home-use can identify respiratory disease subtypes and predict level of risk through an accompanying Respiratory Digital Hub (RDH). By supporting patients in this way, we can keep people out of hospital, managing their condition better, with more effective treatment.